Healthpeak Properties (DOC) Aktienübersicht
Healthpeak Properties, Inc. ist ein Standard & Poor's 500-Unternehmen, das hochwertige Immobilien besitzt, betreibt und entwickelt, die sich auf die Erforschung und Bereitstellung von Gesundheitsleistungen in den Vereinigten Staaten konzentrieren. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 1/6 |
| Dividenden | 4/6 |
Belohnungen
Risikoanalyse
DOC Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Healthpeak Properties, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$19.40 |
| 52-Wochen-Hoch | US$20.82 |
| 52-Wochen-Tief | US$15.70 |
| Beta | 1.03 |
| 1 Monat Veränderung | -0.46% |
| 3 Monate Veränderung | 9.42% |
| 1 Jahr Veränderung | 13.78% |
| 3 Jahre Veränderung | -2.37% |
| 5 Jahre Veränderung | -42.67% |
| Veränderung seit IPO | 265.18% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.
Narrativ-Update • May 29
DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential
Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).Recent updates
Narrativ-Update • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.Narrativ-Update • May 29
DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential
Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).Narrativ-Update • May 13
DOC: Buyback Activity And Raised Earnings Outlook Will Mask Weaker Margin Outlook
Analysts have kept their $16.00 price target on Healthpeak Properties unchanged, citing updated assumptions that include a slightly higher discount rate, a shift to declining revenue growth, lower profit margins, and a much higher future P/E estimate. What's in the News From January 1, 2026 to May 5, 2026, Healthpeak Properties repurchased 5,950,000 shares, representing 0.86% of its stock for US$100 million under its existing buyback program (Key Developments).Seeking Alpha • May 13
Healthpeak Properties: Lab Weakness Creates A Major Re-Rating Opportunity
Summary Healthpeak Properties is still a Buy after the recent rally, supported by strong earnings, a robust dividend, and significant re-rating potential. DOC's Q1 2026 beat on FFO and revenue; completed the Janus Living IPO; and executed major acquisitions, reinforcing portfolio value and future growth prospects. With $1.17 billion in cash and a sustainable 6.2% monthly dividend yield (~70.7% payout ratio), DOC's dividend looks safe despite macroeconomic headwinds, leaving room for more buybacks. Intrinsic value is estimated above current levels even when using conservative assumptions, with upside to >$30/share possible if macro conditions improve and discount rates normalize. Read the full article on Seeking Alpha
Narrativ-Update • Apr 28
DOC: Higher Margins And Earnings Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties by about $0.64 to $25.80 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E are incorporated into their models. What's in the News Healthpeak Properties reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program, closing out a total repurchase of 5,091,156 shares, or 0.73%, for $94.17 million under the authorization announced on July 25, 2024 (Key Developments).Narrativ-Update • Apr 14
DOC: Share Repurchases And Improved Margins Will Support Future Upside Potential
Analysts have slightly raised their price target on Healthpeak Properties to about $26.44, a marginal change from roughly $26.43. The revision reflects updated assumptions related to discount rate, revenue growth, profit margin and a projected future P/E near 98x.Narrativ-Update • Mar 31
DOC: Earnings Guidance And Completed Buyback Will Shape Measured Future Return Potential
Analysts now hold their $16.00 price target on Healthpeak Properties while adjusting underlying assumptions slightly on discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning rather than a major shift in their view of the stock.Narrativ-Update • Mar 16
DOC: Share Repurchases And Stronger Margins Will Support Future Upside Potential
Analysts now estimate Healthpeak Properties' fair value price target at about $26.43, compared with the previous estimate of roughly $26.71. The revision reflects updated views on revenue growth, profit margin and future P/E assumptions.Narrativ-Update • Mar 02
DOC: Earnings Outlook And Completed Buyback Will Highlight Limited Future Upside
Analysts have maintained their $16.00 price target for Healthpeak Properties. They cite only small adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E that together do not materially change their view of the stock’s valuation.Narrativ-Update • Feb 16
DOC: Share Buyback Completion And Earnings Outlook Will Shape Fair Prospects
Analysts have adjusted their price target on Healthpeak Properties from $18.00 to $16.00. The revision reflects updated models that incorporate a slightly higher discount rate, a lower profit margin assumption and a revised future P/E estimate, while also taking into account a higher revenue growth outlook.Narrativ-Update • Feb 02
DOC: Stable Margins And Modest Assumption Shifts Will Support Future Upside Potential
Analysts now estimate fair value for Healthpeak Properties at about US$20.17 per share, compared with roughly US$20.68 previously. The change reflects slightly revised assumptions around discount rates, long term revenue growth, profit margins and future P/E levels.Narrativ-Update • Jan 19
DOC: Share Repurchases And Higher Future P/E Will Support Upside Potential
Analysts have nudged their price target on Healthpeak Properties slightly higher to about US$26.71 from roughly US$26.65, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. Together, these factors shape a modestly revised outlook for the shares.Narrativ-Update • Jan 05
DOC: Completed Buyback And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to about US$20.68 per share from roughly US$20.92, citing slightly higher discount rate assumptions along with modest adjustments to revenue growth, profit margin, and future P/E inputs in their models. What's in the News From July 1, 2025 to September 30, 2025, Healthpeak Properties reported no share repurchases under its current program, with 0 shares bought for US$0 million in that period (Key Developments).Narrativ-Update • Dec 14
DOC: Share Repurchases And Margin Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments) No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments) Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments) Valuation Changes Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.Narrativ-Update • Nov 30
DOC: Lower Discount Rate Will Support Improving Profit Margins Moving Forward
Analysts have modestly increased their price target for Healthpeak Properties from $20.86 to $20.92. This reflects slightly improved forward-looking profit margins and a lower discount rate, although it is partially tempered by a more conservative outlook for revenue growth.Narrativ-Update • Nov 16
DOC: Discount Rate Improvements Will Drive Margin Gains Ahead
Analysts have slightly lowered their price target for Healthpeak Properties from $21.03 to $20.86. They cite modest adjustments in growth and discount rate assumptions, while also noting a marginal improvement in profit margins.Narrativ-Update • Nov 01
DOC: Share Repurchase And Index Removal Will Unlock Future Upside Potential
Analysts have slightly lowered their price target for Healthpeak Properties to $21.03 from $21.19, citing modest reductions in revenue growth and profit margin expectations as key factors behind the revision. What's in the News Healthpeak Properties completed the repurchase of 5,091,156 shares, representing 0.73% of outstanding shares, for $94.17 million under its buyback announced on July 25, 2024 (Key Developments).Narrativ-Update • Oct 17
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly lowered their price target for Healthpeak Properties from $21.31 to $21.19, citing a modest increase in expected discount rates and revenue growth, along with a small dip in projected profit margin. What's in the News Healthpeak Properties, Inc.Narrativ-Update • Oct 03
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.Narrativ-Update • Sep 17
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38. What's in the News Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.Narrativ-Update • Sep 02
Outpatient And Life Science Trends Will Create Future Opportunities
The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53. What's in the News Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.Narrativ-Update • Aug 19
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.Seeking Alpha • Apr 10
Healthpeak Properties: Defensive REIT With Strong Dividend And Post-Merger Upside
Summary Healthpeak Properties is a high-quality healthcare REIT trading at a low valuation, offering 25-30% price appreciation and a ~6.7% annual dividend yield. The successful merger with Physicians Realty Trust has created a dominant healthcare REIT with significant synergies, improving operational performance and tenant diversification. Healthpeak's portfolio benefits from a strong demographic tailwind, robust leasing activity, and strategic focus on outpatient medical buildings and life science properties. Trading at a lower valuation than peers, Healthpeak's strong fundamentals make it an attractive buy for total return and income-focused investors. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Why Healthpeak Is A Smart Buy For Income Investors
Summary Healthpeak Properties offers a compelling investment opportunity with a 5.9% dividend yield, strong operating fundamentals, and an attractive valuation. DOC's diversified healthcare portfolio benefits from limited new supply, robust demand, and strategic loan investments in life sciences for immediate earnings accretion. With a strong balance sheet and a forward P/FFO of 11.2, DOC is well-positioned for long-term growth and potential market-beating returns. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
A REIT Geek Who Likes Healthpeak
Summary Healthpeak Properties is a top healthcare REIT with a robust portfolio, strong fundamentals, and a well-covered 6% yield, making it an attractive investment. Despite recent price declines, Healthpeak's AFFO growth, low leverage, and strategic life-science assets position it for stability and modest growth. The lab space market's tightening supply and increased biotech capital raise Healthpeak's valuation potential, justifying a conservative P/AFFO of 14-16x. At a share price of $16-$18, Healthpeak offers a compelling buy opportunity with an expected annualized return of 16-17%, supported by analyst consensus. Read the full article on Seeking AlphaSeeking Alpha • Dec 22
Healthpeak Properties: I'm Buying The 6% Dividend Yield
Summary Healthpeak Properties has dipped and now offers a 6% dividend yield that's 147% covered by its fiscal 2024 third-quarter FFO. The REIT generated free cash flow in excess of dividend payments during the third quarter. Spiking US 10-year Treasury yield forms a material headwind for stock price growth. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
Healthpeak: Potential Upside Still Exists, But Don't Expect Much
Summary Healthpeak Properties is a BBB+ rated healthcare REIT with a solid portfolio, low leverage, and a well-covered 5.4% yield, offering a conservative 15% annualized return. The company is nearing full valuation but remains attractive due to its stable fundamentals, slight growth prospects, and recent merger benefits. Despite low growth estimates, Healthpeak's conservative P/AFFO of 14.25x suggests a potential upside, making it a "Buy" with a $27/share price target. Healthpeak fulfills all my investment criteria except being cheap, making it a sound investment for conservative, double-digit returns. Read the full article on Seeking Alpha
Neues Narrativ • Aug 21
Strategic Mergers And Key Life Science Leases Propel Revenue And Earnings Growth
Execution of priorities like merger integration and asset sales directly boosts 2024 guidance, signaling positive revenue and earnings impact.Seeking Alpha • Jul 18
Healthpeak: Missing The Boat Above $20/Share
Summary I update on investment in Healthpeak REIT, owning a significant stake with a positive return on investment and yield of over 7%. I highlight the undervaluation of Healthpeak, positive outlook on a diverse portfolio, and caution on current share price above $20. I maintain my thesis on Healthpeak as an attractive buy with conservative double-digit upside potential, based on sound fundamentals and future growth prospects. Read the full article on Seeking AlphaSeeking Alpha • Jul 09
Healthpeak Properties: A 6.1% Yielding Healthcare Trust With Upside
Summary Healthpeak Properties is a leading U.S. real estate investment trust focused on medical office buildings, poised for long-term growth. The merger with Physician Realty Trust has increased the trust's portfolio to 748 properties, with potential for $80 million in synergies. With a steady dividend and strong funds from operations growth, Healthpeak Properties is a compelling investment for passive income investors. Read the full article on Seeking AlphaSeeking Alpha • May 14
Healthpeak Q1 - The "Best" In The Space With A 15% Upside
Summary Healthpeak (DOC) is an attractive healthcare REIT with a diverse portfolio and a yield of over 7%. The company is unlikely to see significant near-term AFFO growth, but offers stability and potential slight growth. The stock is currently undervalued and has a conservative double-digit upside, making it a good buy. Read the full article on Seeking AlphaSeeking Alpha • Apr 12
HealthPeak Properties: A Quality Healthcare REIT That Should Get Back To Dividend Growth
Summary HealthPeak Properties recently closed on its merger with Physicians Realty Trust, which is expected to generate merger-related synergies and be accretive to AFFO. The company reported strong earnings with solid growth in same-store NOI and AFFO. HealthPeak Properties has a strong balance sheet and attractive valuation below peers and the sector median, offering dividend investors a good buying opportunity. Due to the recent merger, I expect the REIT to get back to dividend growth in the near future. The share price may continue to experience volatility due to shrinking sentiment surrounding interest rate cuts in June. Read the full article on Seeking AlphaAktionärsrenditen
| DOC | US Health Care REITs | US Markt | |
|---|---|---|---|
| 7D | -5.2% | -2.6% | 2.0% |
| 1Y | 13.8% | 25.9% | 23.3% |
Rendite im Vergleich zur Industrie: DOC unter dem Niveau der Branche US Health Care REITs , die im vergangenen Jahr eine Rendite von 25.9% erzielte.
Rendite vs. Markt: DOC hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 23.3 erzielte.
Preisvolatilität
| DOC volatility | |
|---|---|
| DOC Average Weekly Movement | 6.1% |
| Health Care REITs Industry Average Movement | 4.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: DOC hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: DOCDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1985 | 411 | Scott Brinker | www.healthpeak.com |
Healthpeak Properties, Inc. ist ein Standard & Poor's 500-Unternehmen, das hochwertige Immobilien besitzt, betreibt und entwickelt, die sich auf die Erforschung und Bereitstellung von Gesundheitsleistungen in den Vereinigten Staaten konzentrieren. Unser Unternehmen wurde ursprünglich 1985 gegründet. Wir sind als REIT in Form einer Dachgesellschaft organisiert.
Healthpeak Properties, Inc.'s Grundlagenzusammenfassung
| DOC grundlegende Statistiken | |
|---|---|
| Marktanteil | US$14.11b |
| Gewinn(TTM) | US$221.63m |
| Umsatz(TTM) | US$2.87b |
60.3x
Kurs-Gewinn-Verhältnis 4.7x
Kurs-Umsatz-VerhältnisIst DOC zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| DOC Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$2.87b |
| Kosten der Einnahmen | US$1.20b |
| Bruttogewinn | US$1.68b |
| Sonstige Ausgaben | US$1.45b |
| Gewinn | US$221.63m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 04, 2026
| Gewinn per Aktie (EPS) | 0.32 |
| Bruttomarge | 58.33% |
| Nettogewinnspanne | 7.72% |
| Schulden/Eigenkapital-Verhältnis | 115.0% |
Wie hat sich DOC auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
6.3%
Aktuelle Dividendenrendite68%
AusschüttungsquoteZahlt DOC eine zuverlässige Dividende?
Siehe DOC Dividendenhistorie und Benchmarks| Healthpeak Properties Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jun 15 2026 |
| Datum der Dividendenzahlung | Jun 26 2026 |
| Tage bis Ex-Dividende | 4 days |
| Tage bis zum Datum der Dividendenzahlung | 7 days |
Zahlt DOC eine zuverlässige Dividende?
Siehe DOC Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/17 12:20 |
| Aktienkurs zum Tagesende | 2026/06/17 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Healthpeak Properties, Inc. wird von 35 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Adam Feinstein | Barclays |